Report Recommends Alternatives to Drug Pricing Transparency Legislation
Value-based reimbursement, focus on middlemen in drug distribution system more likely to reduce prices, provide consumers with valuable information BOSTON – As Massachusetts lawmakers consider healthcare price transparency legislation, a new Pioneer Institute study finds that most new drug pricing transparency laws do not lower consumer out-of-pocket costs, and that expensive and onerous compliance rules would likely put upward pressure on prices. In Will New England See Lower Prices from Drug Pricing Transparency Legislation? report author William Smith, a Pioneer visiting research fellow, reviews recent New England legislative attempts to reduce costs by requiring the disclosure of wholesale drug prices and other information about industry pricing practices. The report argues that most of these new laws will not reduce consumer […]